PU.1 enforces quiescence and limits hematopoietic stem cell expansion during inflammatory stress
Open accessPublished version of a preprint
The DOI matches its Crossref record; 112 of the 112 references it cites were found in a registry or an index; 69 of the 82 sources its claims cite were checked for support.
Abstract
Hematopoietic stem cells (HSCs) are capable of entering the cell cycle to replenish the blood system in response to inflammatory cues; however, excessive proliferation in response to chronic inflammation can lead to either HSC attrition or expansion. The mechanism(s) that limit HSC proliferation and expansion triggered by inflammatory signals are poorly defined. Here, we show that long-term HSCs (HSCLT) rapidly repress protein synthesis and cell cycle genes following treatment with the proinflammatory cytokine interleukin (IL)-1. This gene program is associated with activation of the transcription factor PU.1 and direct PU.1 binding at repressed target genes. Notably, PU.1 is required to repress cell cycle and protein synthesis genes, and IL-1 exposure triggers aberrant protein synthesis and cell cycle activity in PU.1-deficient HSCs. These features are associated with expansion of phenotypic PU.1-deficient HSCs. Thus, we identify a PU.1-dependent mechanism triggered by innate immune stimulation that limits HSC proliferation and pool size. These findings provide insight into how HSCs maintain homeostasis during inflammatory stress.
Overview
CoChat Summary
TL;DR
Chavez et al. show that chronic IL-1 represses cell cycle and protein synthesis genes in long-term hematopoietic stem cells (HSCLT), and that the myeloid transcription factor PU.1 directly binds and enforces this quiescent program. PU.1 deficiency derepresses these genes, allowing IL-1 to drive aberrant protein synthesis, cell cycle entry, and expansion of the phenotypic HSCLT pool.
Key findings
- Chronic IL-1β treatment for 20 d induced >1,400 differentially expressed genes (Padj < 0.05) in SLAM HSCs, with downregulated genes enriched for ribosome biogenesis, rRNA processing, tRNA processing, translation, and cell proliferation pathways; HSCLT remained largely quiescent and showed homeostatic protein synthesis rates despite gene repression.
- PU.1 ChIP-seq in HSC-enriched LSK/Flk2−/CD150+ cells identified 52,127 unique PU.1 peaks, and most IL-1 DEGs had PU.1 peaks within ±20 kb of the TSS (586/694 IL-1–up genes; 599/771 IL-1–down genes), including Myc.
- PU.1KI/KI mice, expressing ∼30% of normal PU.1 in SLAM cells, showed derepression of cell cycle and protein synthesis genes in HSCLT; chronic IL-1 further increased these genes and triggered exuberant protein synthesis, increased cell cycle activity, and expansion of phenotypic HSCLT in bone marrow and spleen.
- In vitro, IL-1 delayed HSCLT division and increased PU.1-EYFP before first division; PU.1 activation via PU.1-ERT similarly delayed division, and the translation inhibitor omacetaxine phenocopied IL-1 by limiting HSCLT cell cycle entry.
Methods
- Mouse models: C57BL/6, PU.1KI/KI, PU.1flox/SCL-CreERT, PU.1-EYFP, GFP-Myc, PU.1-ERT, and H2B-GFP reporter mice; IL-1β was injected i.p. at 0.5 µg daily for 1 or 20 d.
- HSC-enriched SLAM (LSK/Flk2−CD48−CD150+) and HSCLT (LSK/Flk2−CD48−CD150+CD34−EPCR+) populations were analyzed by flow cytometry, cell cycle/Ki-67/DAPI, intracellular Myc and puromycin staining, Fluidigm qRT-PCR, RNA-seq, ChIP-seq, single-cell time-lapse imaging, and in vitro culture with IL-1β, 4-OHT, or omacetaxine.
- RNA-seq differential expression used DESeq2 (Padj < 0.05); ChIP-seq used HOMER peak calling; GSEA, IPA, and GO analyses were performed on DEGs and PU.1-bound gene sets.
Limitations
- The paper states that direct versus indirect effects of IL-1 on HSCLT proliferation in vivo remain to be clarified with bone marrow chimera models, and that future studies are needed to identify which signaling pathways trigger aberrant protein synthesis and cell cycle activity in PU.1-deficient HSCs.
- The paper notes that despite IL-1–mediated repression of protein synthesis genes and slowed in vitro cell cycle progression, protein synthesis rates were not decreased in IL-1–exposed HSCLT in vivo, suggesting the repression may dampen mitogenic signaling rather than block translation outright.
- Evident from the text: most mechanistic evidence comes from mouse models and in vitro culture, with limited human validation; the study also relies heavily on phenotypic HSCLT fractions and reporter mice, and some key experiments use small replicate numbers (e.g., n = 2–3/group in some ChIP-seq or conditional knockout analyses).
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures





![Figure 4. Direct IL-1 stimulation in vitro induces PU.1 and restricts HSCLT cell cycle entry. (A) Representative FACS plots (left) and quantification (right) of cell cycle distribution in HSCLT cultured for 24 h with or without IL-1β (n = 6/group). Data are compiled from three independent experiments. (B) Experimental design for single-cell tracking studies of PU.1-EYFP HSCLT cultured with or without IL-1β. Time to first cell division was tracked via microscopy. (C) Graph showing kinetics of first cell division in HSCLT from B (n = 194 −IL-1β; 139 IL-1β). Data are compiled from three independent experiments. (D) PU.1-EYFP levels in HSCLT before first cell division (n = 137 −IL-1β; 192 +IL-1β). Data are compiled from three independent experiments. Box shows upper and lower quartiles with line showing median value, and whiskers upper and lower 10th percentile and individual dots represent outliers. (E) Hierarchical clustering analysis of PU.1-EYFP expression over time from the start of observation until the first division in PU.1-EYFP HSCLT cultured with or without IL-1 (Euclidean distance with Ward linkage; n = 557 −IL-1β; 489 +IL-1β). Data are compiled from three independent experiments. (F) Quantification of PU.1-EYFP level (as arbitrary units [AU]; left) and time to division (right) of HSCLT cultured with or without IL-1β in E. Individual values (representing means from cells cultured either with or without IL-1β in an experiment) are shown with bars representing mean values (n = 6). Data are compiled from three independent experiments. (G) Distribution of HSCLT from E in different clusters based on culture with or without IL-1β. Data are compiled from three independent experiments. (H) Experimental design for Fluidigm qRT-PCR array analysis of HSCLT cultured with or without IL-1β for 12 h. (I) Quantification by Fluidigm qRT-PCR array of cell cycle and protein synthesis gene expression in HSCLT from F (n = 8/group). Data are expressed as log10 fold expression versus −IL-1β. Box represents upper and lower quartiles with line representing median value. Whiskers represent minimum and maximum values. Data are representative of two independent experiments. (J) Experimental design for cell cycle analysis of HSCLT cultured with or without IL-1β and with or without 100 nM Oma for 24 h. (K) Representative FACS plots (left) and quantification (right) of cell cycle distribution in HSCLT from H (n = 3/group). Data are from one experiment. (L) Proportion of HSCLT with >2N DAPI signal from H. Individual values are shown with means (horizontal line). *, P < 0.05; **, P < 0.01; ***, P < 0.001 by Mann-Whitney U test or one-way ANOVA with Tukey’s test in F, G, K, and L. Error bars represent SD. See also Fig. S3.](https://figures.cochat.ai/paper-figures/3283b30cd4854603acf61aaaae485d40/pu-1-enforces-quiescence-and-limits-hematopoietic-stem-cell-expansion-during-figure-4.jpg)






Verification
Claims the paper makes
46 Valid · 1 Not valid · 3 Not checked · 122 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Consistent with prior work (Signer et al., 2014), puro incorporation rates in HSCLT, SLAM cells, and MPP4 were all similar (Fig. S1 G)”
§ PU.1 enforces quiescence and limits hematopoietic stem cell expansion during inflammatory stress > Results > Chronic IL-1 induces repression of cell cycle and protein synthesis genes in long-term HSCs (HSCLT)
What the sources say
- Partly supportedcites Signer et al., 2014 matched to “Haematopoietic stem cells require a highly regulated protein synthesis rate” (2014) sourceExperimental — accuracy not yet measured
In “HSCs synthesize less protein per hour” (page unavailable), the paper reports similar OP-Puro incorporation in CD150−CD48−LSK MPPs and CD150+CD48−LSK HSCs. It does not separately report incorporation rates for the specifically named HSCLT, SLAM, and MPP4 populations, so it supports the general comparison but not the claim at that level of specificity. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Interestingly, activation of this gene program relies, at least in part, on IL-1 signaling (Hernandez et al., 2020).”
§ PU.1 enforces quiescence and limits hematopoietic stem cell expansion during inflammatory stress > Introduction
What the sources say
- Partly supportedcites Hernandez et al., 2020 matched to “Pro-inflammatory cytokine blockade attenuates myeloid expansion in a murine model of rheumatoid arthritis” (2020) sourceExperimental — accuracy not yet measured
The Results section on cytokine blockade (page unavailable) reports that the IL-1 receptor blocker anakinra partially normalized expression of proliferation-arrest genes in HSC from mice with collagen-induced arthritis. This supports a possible contribution from IL-1 signaling, but the paper does not establish that activation of the program relies on it: HSC cell-cycle distribution was unchanged, and the Discussion says anakinra’s effects could be indirect. (LLM, conf=0.84)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Previous work from our group demonstrates that acute IL-1 exposure drives myeloid cell overproduction in vivo via precocious activation of the master myeloid transcription factor PU.1 (Pietras et al., 2016) in HSC.”
§ PU.1 enforces quiescence and limits hematopoietic stem cell expansion during inflammatory stress > Introduction
What the sources say
- Supportedcites Pietras et al., 2016 matched to “Chronic interleukin-1 exposure drives haematopoietic stem cells towards precocious myeloid differentiation at the expense of self-renewal” (2016) source
The Results section, “Haematopoietic remodelling following IL-1 exposure” (page not provided), says that in vivo IL-1 exposure rapidly activates a PU.1-mediated myeloid differentiation program in HSCs and amplifies myeloid cell production. The Results section, “Precocious activation of a PU.1 molecular circuit” (page not provided), also reports rapid PU.1 activation after IL-1 exposure and its role in accelerated myeloid differentiation. (LLM, conf=0.92)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“We recently found that quiescent HSCs downregulate numerous protein synthesis and cell proliferation genes in a mouse model of chronic rheumatoid arthritis (Hernandez et al., 2020).”
§ PU.1 enforces quiescence and limits hematopoietic stem cell expansion during inflammatory stress > Introduction
What the sources say
- Supportedcites Hernandez et al., 2020 matched to “Pro-inflammatory cytokine blockade attenuates myeloid expansion in a murine model of rheumatoid arthritis” (2020) source
The Results section (page not provided) reports that HSCs from mice with collagen-induced arthritis retained a quiescent phenotype. It also reports downregulated genes involved in protein translation and cell-cycle progression, matching the claim. (LLM, conf=0.93)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“These findings imply the existence of a braking mechanism that limits HSC cell cycle entry in response to chronic inflammatory stress (Pietras et al., 2016; Rabe et al., 2020).”
§ PU.1 enforces quiescence and limits hematopoietic stem cell expansion during inflammatory stress > Introduction
What the sources say
- Partly supportedcites Pietras et al., 2016 matched to “Chronic interleukin-1 exposure drives haematopoietic stem cells towards precocious myeloid differentiation at the expense of self-renewal” (2016) sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) reports that the HSC pool remains intact after chronic IL-1 exposure and suggests that a quiescent HSC subset may replenish responsive cells. That provides a basis for the citing authors’ inference, but the paper does not identify a braking mechanism limiting cell-cycle entry; the Results instead report increased HSC division after IL-1 treatment. (LLM, conf=0.80)
- Supportedcites Rabe et al., 2020 matched to “CD34 and EPCR coordinately enrich functional murine hematopoietic stem cells under normal and inflammatory conditions” (2020) source
In Results (‘The EPCR+/CD34− SLAM fraction remains quiescent following chronic IL-1 exposure’; page not provided), the paper reports minimal cell-cycle induction during chronic IL-1 exposure and suggests an Rb-mediated ‘braking’ mechanism in two EPCR− fractions. It also reports reduced expression of genes crucial for HSC cell-cycle entry in the EPCR+/CD34− fraction. The claim appropriately frames a braking mechanism as an implication, rather than an established cause. (LLM, conf=0.88)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
101 more claims · 13 with their cited sources checked
Create a free account to see all 172 claims and every source verdict.
- Probably not a substantial claim. 35
- It may state two separate claims as one. 43
- The quote only partly states this claim. 2
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“PU.1 has also been identified as a master regulator in HSC cell fate decisions and homing through the interaction with a variety of regulatory factors.34,35”
From PELI2 regulates early B-cell progenitor differentiation and related leukemia via the IL-7R expression (2023) · cites this paper as [35]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Indeed, IL-1 can stimulate HSC proliferation, driving their myeloid differentiation at the expense of self-renewal, thus eroding their repopulating capacity.28,49,50”
From Aging drives Tet2 +/− clonal hematopoiesis via IL-1 signaling (2023) · cites this paper as [50]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In phenotypically defined long-term HSC, increased PU.1 levels drive 1) activation of myeloid differentiation gene programs and 2) repression of cell proliferation (Chavez et al., 2021), thereby limiting the expansion of the HSC pool.”
From PU.1 is required to restrain myelopoiesis during chronic inflammatory stress (2023) · cites this paper as Chavez et al., 2021
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“PU.1 maintains HSC quiescence during inflammatory stress by limiting protein production and suppressing cell cycle progression, thus preventing excessive HSC proliferation 20.”
From USP7 sustains hematopoietic stem cell homeostasis partially via PU.1 stabilization (2026) · cites this paper as [20]
The cited source says what the claim attributes to it.
In the citing paper
“We previously showed that PU.1 deficiency leads to increased proliferation in HSCLT following IL-1β stimulation, thereby driving expansion of these cells in vivo (Chavez et al., 2021).”
From PU.1 is required to restrain myelopoiesis during chronic inflammatory stress (2023) · cites this paper as Chavez et al., 2021
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ PU.1 enforces quiescence and limits hematopoietic stem cell expansion during inflammatory stress > Results > Direct IL-1 stimulation in vitro induces PU.1 and restricts HSCLT cell cycle entry
“(K) Representative FACS plots (left) and quantification (right) of cell cycle distribution in HSCLT from H (n = 3/group). Data are from one experiment. (L) Proportion of HSCLT with >2N DAPI signal from H.”
§ PU.1 enforces quiescence and limits hematopoietic stem cell expansion during inflammatory stress > Results > Direct IL-1 stimulation in vitro induces PU.1 and restricts HSCLT cell cycle entry
“(J) Experimental design for cell cycle analysis of HSCLT cultured with or without IL-1β and with or without 100 nM Oma for 24 h.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ PU.1 enforces quiescence and limits hematopoietic stem cell expansion during inflammatory stress > Results > IL-1–induced gene repression is associated with increased PU.1 levels
“(I) Representative FACS plots (left) and quantification (right) showing GFP-Myc expression levels in PU.1lo and PU.1hi SLAM cell fractions from mice in C.”
§ PU.1 enforces quiescence and limits hematopoietic stem cell expansion during inflammatory stress > Results > IL-1–induced gene repression is associated with increased PU.1 levels
“As predicted by our data, phenotypic HSCLT expressed elevated levels of PU.1-EYFP, whereas GFP-Myc levels were reduced (Fig. 3, H and I).”
Citations
Cites
Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources
Huang, D. W., Sherman, B. T., & Lempicki, R. A. (2009) · Nature Protocols · doi:10.1038/nprot.2008.211 · Cited by 35,890
Cutadapt removes adapter sequences from high-throughput sequencing reads
Martin, M. (2011) · EMBnet.journal · doi:10.14806/ej.17.1.200 · Cited by 33,889 · cited 1×
“Fastq read files were trimmed using Cutadapt (Martin, 2011).”
MethodGraph-based genome alignment and genotyping with HISAT2 and HISAT-genotype
Kim, D., Paggi, J. M., Park, C., Bennett, C., & Salzberg, S. L. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0201-4 · Cited by 15,022 · cited 1×
“The trimmed reads were mapped to mm10 mouse genome using HISAT2 (Kim et al., 2019).”
MethodHeinz, S., Benner, C., Spann, N., Bertolino, E., Lin, Y. C., Laslo, P., Cheng, J. X., Murre, C., Singh, H., & Glass, C. K. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.05.004 · Cited by 13,382 · cited 3×
“S4F) at different timepoints post induction (Heinz et al., 2010).”
BackgroundMethodInfluentialMetsalu, T., & Vilo, J. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv468 · Cited by 3,709 · cited 1×
“ee/clustvis) (Metsalu and Vilo, 2015).”
InteractiVenn: a web-based tool for the analysis of sets through Venn diagrams
Heberle, H., Meirelles, G. V., da Silva, F. R., Telles, G. P., & Minghim, R. (2015) · BMC Bioinformatics · doi:10.1186/s12859-015-0611-3 · Cited by 2,580
The bone marrow niche for haematopoietic stem cells
Morrison, S. J., & Scadden, D. T. (2014) · Nature · doi:10.1038/nature12984 · Cited by 2,451 · cited 1×
“, 2020), and signals generated from the bone marrow (BM) niche (Morrison and Scadden, 2014).”
BackgroundWilson, A., Laurenti, E., Oser, G., van der Wath, R. C., Blanco-Bose, W., Jaworski, M., Offner, S., Dunant, C. F., Eshkind, L., Bockamp, E., et al. (2008) · Cell · doi:10.1016/j.cell.2008.10.048 · Cited by 1,908 · cited 3×
“…capacity even under a variety of inflammatory stress conditions (Bujanover et al., 2018; Hernandez et al., 2020; Pietras et al., 2014; Pietras et al., 2016; Rabe et al., 2020; Wilson et al., 2008; Zhao et al., 2019), implying the existence of mechanism(s) that prevent spurious HSC cell cycle entry.”
BackgroundOverview of the IL ‐1 family in innate inflammation and acquired immunity
Dinarello, C. A. (2018) · Immunological Reviews · doi:10.1111/imr.12621 · Cited by 1,866 · cited 3×
“IL-1 is produced in response to a wide variety of physiological stress conditions including aging, chronic inflammatory disease, myeloablative treatments such as radiation and/or chemotherapy, obesity and cellular senescence (Dinarello, 2018; Laberge et al., 2015).”
BackgroundInfluentialIFNα activates dormant haematopoietic stem cells in vivo
Essers, M. A. G., Offner, S., Blanco-Bose, W. E., Waibler, Z., Kalinke, U., Duchosal, M. A., & Trumpp, A. (2009) · Nature · doi:10.1038/nature07815 · Cited by 1,368
Laberge, R.-M., Sun, Y., Orjalo, A. V., Patil, C. K., Freund, A., Zhou, L., Curran, S. C., Davalos, A. R., Wilson-Edell, K. A., Liu, S., et al. (2015) · Nature Cell Biology · doi:10.1038/ncb3195 · Cited by 1,160 · cited 1×
“treatments, such as radiation and/or chemotherapy; obesity; and cellular senescence (Dinarello, 2018; Laberge et al., 2015).”
Backgroundc-Myc controls the balance between hematopoietic stem cell self-renewal and differentiation
Wilson, A., Murphy, M. J., Oskarsson, T., Kaloulis, K., Bettess, M. D., Oser, G. M., Pasche, A.-C., Knabenhans, C., MacDonald, H. R., & Trumpp, A. (2004) · Genes & Development · doi:10.1101/gad.313104 · Cited by 823 · cited 1×
“Likewise, IL-1 downregulates expression of c-Myc, a crucial upstream regulator of protein synthesis and cell cycle genes that leads to defective cell cycle entry if deleted in stem cells (Laurenti et al., 2008; Scognamiglio et al., 2016; Wilson et al., 2004).”
BackgroundChronic variable stress activates hematopoietic stem cells
Heidt, T., Sager, H. B., Courties, G., Dutta, P., Iwamoto, Y., Zaltsman, A., von zur Muhlen, C., Bode, C., Fricchione, G. L., Denninger, J., et al. (2014) · Nature Medicine · doi:10.1038/nm.3589 · Cited by 803
mTORC1 controls the adaptive transition of quiescent stem cells from G0 to GAlert
Rodgers, J. T., King, K. Y., Brett, J. O., Cromie, M. J., Charville, G. W., Maguire, K. K., Brunson, C., Mastey, N., Liu, L., Tsai, C.-R., et al. (2014) · Nature · doi:10.1038/nature13255 · Cited by 776
CCAAT-Enhancer Binding Protein: A Component of a Differentiation Switch
Umek, R. M., Friedman, A. D., & McKnight, S. L. (1991) · Science · doi:10.1126/science.1987644 · Cited by 712
Pietras, E. M., Mirantes-Barbeito, C., Fong, S., Loeffler, D., Kovtonyuk, L. V., Zhang, S., Lakshminarasimhan, R., Chin, C. P., Techner, J.-M., Will, B., et al. (2016) · Nature Cell Biology · doi:10.1038/ncb3346 · Cited by 689 · cited 10×
“In vitro culture assays Purified HSCLT were cultured using a similar protocol as that previously published (Pietras et al., 2016).”
BackgroundMethodResultInfluentialSelf-citationHaematopoietic stem cells require a highly regulated protein synthesis rate
Signer, R. A. J., Magee, J. A., Salic, A., & Morrison, S. J. (2014) · Nature · doi:10.1038/nature13035 · Cited by 674 · cited 7×
“Likewise, deletion of Pten, which dephosphorylates and inhibits the eIF activator mTOR, leads to similar aberrant HSC activity and hypersensitivity to inflammatory factors such as G-CSF and IFNs (Porter et al., 2016; Signer et al., 2014).”
BackgroundResultInfluentialPronk, C. J. H., Rossi, D. J., Månsson, R., Attema, J. L., Norddahl, G. L., Chan, C. K. F., Sigvardsson, M., Weissman, I. L., & Bryder, D. (2007) · Cell Stem Cell · doi:10.1016/j.stem.2007.07.005 · Cited by 671 · cited 3×
“…observed lineage-specific expression patterns of PU.1 and Myc in HSPC from these mice, with granulocytemacrophage progenitors (GMP; LK/CD41-/FcgR+; (Pronk et al., 2007)) expressing high levels of PU.1, whereas phenotypic CFU-erythroid (CFU-E; LK/CD41-/FcgR-/CD150-/CD105+) and megakaryocyte…”
BackgroundInfluentialExit from dormancy provokes DNA-damage-induced attrition in haematopoietic stem cells
Walter, D., Lier, A., Geiselhart, A., Thalheimer, F. B., Huntscha, S., Sobotta, M. C., Moehrle, B., Brocks, D., Bayindir, I., Kaschutnig, P., et al. (2015) · Nature · doi:10.1038/nature14131 · Cited by 619
Self-citationAnalysis of histone 2B-GFP retention reveals slowly cycling hematopoietic stem cells
Foudi, A., Hochedlinger, K., Van Buren, D., Schindler, J. W., Jaenisch, R., Carey, V., & Hock, H. (2009) · Nature Biotechnology · doi:10.1038/nbt.1517 · Cited by 586
Gfi-1 restricts proliferation and preserves functional integrity of haematopoietic stem cells
Hock, H., Hamblen, M. J., Rooke, H. M., Schindler, J. W., Saleque, S., Fujiwara, Y., & Orkin, S. H. (2004) · Nature · doi:10.1038/nature02994 · Cited by 541 · cited 1×
“1 target (Hock et al., 2004; Porse et al., 2005; Pulikkan et al., 2017; Staber et al., 2013; Umek et al., 1991; Zeng et al., 2004).”
Inflammatory modulation of HSCs: viewing the HSC as a foundation for the immune response
King, K. Y., & Goodell, M. A. (2011) · Nature Reviews Immunology · doi:10.1038/nri3062 · Cited by 538 · cited 1×
“blative injury (Harrison and Lerner, 1991), demonstrating that HSCs can replenish cells lost to disruptions in BM homeostasis (King and Goodell, 2011).”
BackgroundAcute myeloid leukemia induced by graded reduction of a lineage-specific transcription factor, PU.1.
Rosenbauer, F., Wagner, K., Kutok, J. L., Iwasaki, H., Le Beau, M. M., Okuno, Y., Akashi, K., Fiering, S., & Tenen, D. G. (2004) · Nature Genetics · doi:10.1038/ng1361 · Cited by 506
Haas, S., Hansson, J., Klimmeck, D., Loeffler, D., Velten, L., Uckelmann, H., Wurzer, S., Prendergast, Á. M., Schnell, A., Hexel, K., et al. (2015) · Cell Stem Cell · doi:10.1016/j.stem.2015.07.007 · Cited by 471
Self-citationCell cycle regulation in hematopoietic stem cells
Pietras, E. M., Warr, M. R., & Passegué, E. (2011) · Journal of Cell Biology · doi:10.1083/jcb.201102131 · Cited by 447 · cited 2×
“Introduction Hematopoietic stem cell (HSC) quiescence promotes lifelong blood regeneration and is controlled by a complex regulatory network, including cell-intrinsic transcription factors and epigenetic modifiers (Pietras et al., 2011), organelle homeostasis mechanisms (Hinge et al.”
BackgroundSelf-citationKirstetter, P., Anderson, K., Porse, B. T., Jacobsen, S. E. W., & Nerlov, C. (2006) · Nature Immunology · doi:10.1038/ni1381 · Cited by 446 · cited 2×
“1-EYFP and GFP-Myc reporter mouse strains (Fig. 3 C; Hoppe et al., 2016; Huang et al., 2008; Kirstetter et al., 2006).”
BackgroundInflammation: a key regulator of hematopoietic stem cell fate in health and disease
Pietras, E. M. (2017) · Blood · doi:10.1182/blood-2017-06-780882 · Cited by 417 · cited 9×
“While transient proliferative responses to stress are crucial adaptations that promote organismal survival, long-term loss of HSC quiescence can lead to bone marrow failure, overproduction of potentially toxic cell types and/or hematological malignancy (Pietras, 2017).”
BackgroundInfluentialSelf-citationObservation of Antigen-Dependent CD8+ T-Cell/ Dendritic Cell Interactions in Vivo
Schaefer, B. C., Schaefer, M. L., Kappler, J. W., Marrack, P., & Kedl, R. M. (2001) · Cellular Immunology · doi:10.1006/cimm.2001.1895 · Cited by 393 · cited 1×
“For H2B-GFP dilution analysis, we used splenocytes from Ubc-GFP mice (Schaefer et al., 2001) as a GFP compensation control to ensure comparable brightness to the GFP signal.”
MethodTNF-α Coordinates Hematopoietic Stem Cell Survival and Myeloid Regeneration
Yamashita, M., & Passegué, E. (2019) · Cell Stem Cell · doi:10.1016/j.stem.2019.05.019 · Cited by 387
A BaSiC tool for background and shading correction of optical microscopy images
Peng, T., Thorn, K., Schroeder, T., Wang, L., Theis, F. J., Marr, C., & Navab, N. (2017) · Nature Communications · doi:10.1038/ncomms14836 · Cited by 369
Self-citationc-Myc enhances protein synthesis and cell size during B lymphocyte development
Iritani, B. M., & Eisenman, R. N. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.23.13180 · Cited by 364 · cited 1×
“Oma and IL-1 also reduced the forward scatter (FSC) profile of cultured HSC, consistent with previous observations correlating cell size and biosynthetic activity (Iritani and Eisenman, 1999; Scognamiglio et al., 2016) (Fig.”
ResultCancer as a disease of old age: changing mutational and microenvironmental landscapes
Laconi, E., Marongiu, F., & DeGregori, J. (2020) · British Journal of Cancer · doi:10.1038/s41416-019-0721-1 · Cited by 348 · cited 1×
“These findings are consistent with the theory of adaptive oncogenesis, which stipulates that environmental factors associated with tissue decline, such as inflammation, are crucial drivers of oncogenesis by selecting for emergent phenotypes, such as increased proliferation, self-renewal, or survival, that are linked c…”
ResultSelf-citationZambetti, N. A., Ping, Z., Chen, S., Kenswil, K. J. G., Mylona, M. A., Sanders, M. A., Hoogenboezem, R. M., Bindels, E. M. J., Adisty, M. N., Van Strien, P. M. H., et al. (2016) · Cell stem cell · doi:10.1016/j.stem.2016.08.021 · Cited by 342
p57 is required for quiescence and maintenance of adult hematopoietic stem cells
Matsumoto, A., Takeishi, S., Kanie, T., Susaki, E., Onoyama, I., Tateishi, Y., Nakayama, K., & Nakayama, K. I. (2011) · Cell stem cell · doi:10.1016/j.stem.2011.06.014 · Cited by 329 · cited 1×
“However, tight regulation of cell cycle activity is crucial for maintaining the long-term functional integrity of the HSC pool (Matsumoto et al., 2011; Pietras et al., 2011).”
BackgroundTranscription factor Gfi1 regulates self‐renewal and engraftment of hematopoietic stem cells
Zeng, H., Yücel, R., Kosan, C., Klein‐Hitpass, L., & Möröy, T. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600419 · Cited by 329
Pietras, E. M., Lakshminarasimhan, R., Techner, J.-M., Fong, S., Flach, J., Binnewies, M., & Passegué, E. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20131043 · Cited by 323 · cited 4×
“Results Chronic IL-1 induces repression of cell cycle and protein synthesis genes in long-term HSCs (HSCLT) We previously found that HSCs maintain a largely quiescent state during chronic inflammatory stress driven by IL-1 and chronic inflammatory arthritis (Hernandez et al., 2020; Pietras, 2017; Pietras et al., 2014;…”
BackgroundInfluentialSelf-citationHematopoietic stem cell function and survival depend on c-Myc and N-Myc activity
Laurenti, E., Varnum-Finney, B., Wilson, A., Ferrero, I., Blanco-Bose, W. E., Ehninger, A., Knoepfler, P. S., Cheng, P.-F., MacDonald, H. R., Eisenman, R. N., et al. (2008) · Cell Stem Cell · doi:10.1016/j.stem.2008.09.005 · Cited by 305
Positive Feedback Between PU.1 and the Cell Cycle Controls Myeloid Differentiation
Kueh, H. Y., Champhekar, A., Nutt, S. L., Elowitz, M. B., & Rothenberg, E. V. (2013) · Science · doi:10.1126/science.1240831 · Cited by 273 · cited 1×
“1 accumulation during myeloid differentiation (Fukuchi et al., 2008; Kueh et al., 2013).”
Takizawa, H., Fritsch, K., Kovtonyuk, L. V., Saito, Y., Yakkala, C., Jacobs, K., Ahuja, A. K., Lopes, M., Hausmann, A., Hardt, W.-D., et al. (2017) · Cell Stem Cell · doi:10.1016/j.stem.2017.06.013 · Cited by 273 · cited 13×
“2A), supporting a direct signaling mechanism via the MyD88 axis downstream of IL-1R (Fig.”
BackgroundInfluentialMyc Depletion Induces a Pluripotent Dormant State Mimicking Diapause
Scognamiglio, R., Cabezas-Wallscheid, N., Thier, M. C., Altamura, S., Reyes, A., Prendergast, Á. M., Baumgärtner, D., Carnevalli, L. S., Atzberger, A., Haas, S., et al. (2016) · Cell · doi:10.1016/j.cell.2015.12.033 · Cited by 271 · cited 1×
“Likewise, IL-1 downregulates expression of Myc, a crucial upstream regulator of protein synthesis and cell cycle genes that leads to defective cell cycle entry if deleted in stem cells (Laurenti et al., 2008; Scognamiglio et al., 2016; Wilson et al., 2004).”
BackgroundCarey, A., Edwards, D. K., Eide, C. A., Newell, L., Traer, E., Medeiros, B. C., Pollyea, D. A., Deininger, M. W., Collins, R. H., Tyner, J. W., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.03.018 · Cited by 270
Walsh, J. C., DeKoter, R. P., Lee, H.-J., Smith, E. D., Lancki, D. W., Gurish, M. F., Friend, D. S., Stevens, R. L., Anastasi, J., & Singh, H. (2002) · Immunity · doi:10.1016/s1074-7613(02)00452-1 · Cited by 262
Chronic Infection Depletes Hematopoietic Stem Cells through Stress-Induced Terminal Differentiation
Matatall, K. A., Jeong, M., Chen, S., Sun, D., Chen, F., Mo, Q., Kimmel, M., & King, K. Y. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.11.031 · Cited by 262 · cited 5×
“Likewise, deletion of Pten, which dephosphorylates and inhibits the eIF activator mTOR, leads to similar aberrant HSC activity and hypersensitivity to inflammatory factors such as G-CSF and IFNs (Porter et al., 2016; Signer et al., 2014).”
BackgroundInfluentialRestraining Lysosomal Activity Preserves Hematopoietic Stem Cell Quiescence and Potency
Liang, R., Arif, T., Kalmykova, S., Kasianov, A., Lin, M., Menon, V., Qiu, J., Bernitz, J. M., Moore, K., Lin, F., et al. (2020) · Cell Stem Cell · doi:10.1016/j.stem.2020.01.013 · Cited by 254 · cited 1×
“, 2011), organelle homeostasis mechanisms (Hinge et al., 2020; Liang et al., 2020), and signals generated from the bone marrow (BM) niche (Morrison and Scadden, 2014).”
BackgroundRisks of myeloid malignancies in patients with autoimmune conditions
Anderson, L. A., Pfeiffer, R. M., Landgren, O., Gadalla, S., Berndt, S. I., & Engels, E. A. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6604935 · Cited by 253
Smith, M. A., Choudhary, G. S., Pellagatti, A., Choi, K., Bolanos, L. C., Bhagat, T. D., Gordon-Mitchell, S., Von Ahrens, D., Pradhan, K., Steeples, V., et al. (2019) · Nature Cell Biology · doi:10.1038/s41556-019-0314-5 · Cited by 247 · cited 1×
“Aberrant signaling via IL-1 and the downstream IL-1 receptor associated kinase/TNF receptor associated factor pathway shared by IL-1R and TLRs has been implicated as a driver of survival and/or expansion of MDS and myeloid leukemia stem cells (Ågerstam et al., 2016; Askmyr et al., 2013; Barreyro et al., 2012; Carey et…”
BackgroundVangala, R. K., Heiss-Neumann, M. S., Rangatia, J. S., Singh, S. M., Schoch, C., Tenen, D. G., Hiddemann, W., & Behre, G. (2003) · Blood · doi:10.1182/blood-2002-04-1288 · Cited by 245
Harrison, D., & Lerner, C. (1991) · Blood · doi:10.1182/blood.v78.5.1237.1237 · Cited by 242
Deregulation of innate immune and inflammatory signaling in myelodysplastic syndromes
Gañán-Gómez, I., Wei, Y., Starczynowski, D. T., Colla, S., Yang, H., Cabrero-Calvo, M., Bohannan, Z. S., Verma, A., Steidl, U., & Garcia-Manero, G. (2015) · Leukemia · doi:10.1038/leu.2015.69 · Cited by 236
Chronic immune response dysregulation in MDS pathogenesis
Barreyro, L., Chlon, T. M., & Starczynowski, D. T. (2018) · Blood · doi:10.1182/blood-2018-03-784116 · Cited by 226 · cited 4×
“Chronic inflammation, often associated with increased IL-1 activity, is a common phenotype in individuals at risk for hematological malignancy, which can be related to several pre-existing factors including aging/tissue decline, genotoxin exposure, metabolic dysfunction and/or autoimmune disease (Barreyro et al., 2018…”
BackgroundInfluentialMirantes, C., Passegué, E., & Pietras, E. M. (2014) · Experimental Cell Research · doi:10.1016/j.yexcr.2014.08.017 · Cited by 211 · cited 1×
“Pro-inflammatory cytokine induction, which is common amongst nearly all physiological stressors, can drive HSC proliferation or differentiation (Mirantes et al., 2014).”
BackgroundSelf-citationMueller, B. U., Pabst, T., Fos, J., Petkovic, V., Fey, M. F., Asou, N., Buergi, U., & Tenen, D. G. (2006) · Blood · doi:10.1182/blood-2005-07-3068 · Cited by 207 · cited 2×
“On the other hand, loss-of function mutations in PU.1 itself are rarely observed in hematological malignancy, though a wide array of myeloid leukemia-associated oncogenic lesions can interfere with PU.1 expression or function, including PML/RARA, AML1-ETO, NPM1c, and mitogenic kinase mutations in BCR/ABL and Flt3ITD (…”
BackgroundEarly myeloid lineage choice is not initiated by random PU.1 to GATA1 protein ratios
Hoppe, P. S., Schwarzfischer, M., Loeffler, D., Kokkaliaris, K. D., Hilsenbeck, O., Moritz, N., Endele, M., Filipczyk, A., Gambardella, A., Ahmed, N., et al. (2016) · Nature · doi:10.1038/nature18320 · Cited by 206
Self-citationGöthert, J. R., Gustin, S. E., Hall, M. A., Green, A. R., Göttgens, B., Izon, D. J., & Begley, C. G. (2005) · Blood · doi:10.1182/blood-2004-08-3037 · Cited by 203
Barreyro, L., Will, B., Bartholdy, B., Zhou, L., Todorova, T. I., Stanley, R. F., Ben-Neriah, S., Montagna, C., Parekh, S., Pellagatti, A., et al. (2012) · Blood · doi:10.1182/blood-2012-01-404699 · Cited by 201
Hinge, A., He, J., Bartram, J., Javier, J., Xu, J., Fjellman, E., Sesaki, H., Li, T., Yu, J., Wunderlich, M., et al. (2020) · Cell Stem Cell · doi:10.1016/j.stem.2020.01.016 · Cited by 200
Targeting IRAK1 as a therapeutic approach for myelodysplastic syndrome
Rhyasen, G. W., Bolanos, L., Fang, J., Jerez, A., Wunderlich, M., Rigolino, C., Mathews, L., Ferrer, M., Southall, N., Guha, R., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.05.006 · Cited by 199 · cited 1×
“Indeed, blockade of these pathways can limit and/or reverse disease progression (Carey et al., 2017; Mitchell et al., 2018; Rhyasen et al., 2013; Zhang et al., 2016).”
BackgroundSoftware tools for single-cell tracking and quantification of cellular and molecular properties
Hilsenbeck, O., Schwarzfischer, M., Skylaki, S., Schauberger, B., Hoppe, P. S., Loeffler, D., Kokkaliaris, K. D., Hastreiter, S., Skylaki, E., Filipczyk, A., et al. (2016) · Nature Biotechnology · doi:10.1038/nbt.3626 · Cited by 163
Self-citationStaber, P. B., Zhang, P., Ye, M., Welner, R. S., Nombela-Arrieta, C., Bach, C., Kerenyi, M., Bartholdy, B. A., Zhang, H., Alberich-Jordà, M., et al. (2013) · Molecular Cell · doi:10.1016/j.molcel.2013.01.007 · Cited by 158 · cited 11×
“Our data agree with prior studies showing that PU.1 deficiency leads to de-repression of Myc and numerous cell cycle genes including Cdk1 and E2f1 (Rosenbauer et al., 2004; Staber et al., 2013; Will et al., 2015), which is exacerbated by IL-1 exposure.”
BackgroundMethodResultInfluentialSelf-citationMuto, T., Walker, C. S., Choi, K., Hueneman, K., Smith, M. A., Gul, Z., Garcia-Manero, G., Ma, A., Zheng, Y., & Starczynowski, D. T. (2020) · Nature Immunology · doi:10.1038/s41590-020-0663-z · Cited by 155 · cited 1×
“Aberrant signaling via IL-1 and the downstream IL-1 receptor associated kinase/TNF receptor associated factor pathway shared by IL-1R and TLRs has been implicated as a driver of survival and/or expansion of MDS and myeloid leukemia stem cells (Ågerstam et al., 2016; Askmyr et al., 2013; Barreyro et al., 2012; Carey et…”
BackgroundAging-associated inflammation promotes selection for adaptive oncogenic events in B cell progenitors
Henry, C. J., Casás-Selves, M., Kim, J., Zaberezhnyy, V., Aghili, L., Daniel, A. E., Jimenez, L., Azam, T., McNamee, E. N., Clambey, E. T., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci83024 · Cited by 148
Self-citationZhao, M., Tao, F., Venkatraman, A., Li, Z., Smith, S. E., Unruh, J., Chen, S., Ward, C., Qian, P., Perry, J. M., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2018.12.093 · Cited by 146
Ueda, Y., Cain, D. W., Kuraoka, M., Kondo, M., & Kelsoe, G. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0803961 · Cited by 138
Schuettpelz, L. G., Borgerding, J. N., Christopher, M. J., Gopalan, P. K., Romine, M. P., Herman, A. C., Woloszynek, J. R., Greenbaum, A. M., & Link, D. C. (2014) · Leukemia · doi:10.1038/leu.2014.68 · Cited by 138 · cited 3×
“Notably, HSC proliferate in response to IFNs (Ehninger et al., 2014; Essers et al., 2009; Matatall et al., 2016), LPS (Takizawa et al., 2017), G-CSF (Schuettpelz et al., 2014), TNF (Yamashita and Passegue, 2019) and interleukin (IL)-1 (Hemmati et al., 2019; Weisser et al., 2016).”
NF-κB/STAT5/miR-155 network targets PU.1 in FLT3-ITD-driven acute myeloid leukemia
Gerloff, D., Grundler, R., Wurm, A. A., Bräuer-Hartmann, D., Katzerke, C., Hartmann, J.-U., Madan, V, Müller-Tidow, C., Duyster, J., Tenen, D. G., et al. (2015) · Leukemia · doi:10.1038/leu.2014.231 · Cited by 135
Selective killing of candidate AML stem cells by antibody targeting of IL1RAP
Askmyr, M., Ågerstam, H., Hansen, N., Gordon, S., Arvanitakis, A., Rissler, M., Juliusson, G., Richter, J., Järås, M., & Fioretos, T. (2013) · Blood · doi:10.1182/blood-2012-09-458935 · Cited by 127
Will, B., Vogler, T. O., Narayanagari, S., Bartholdy, B., Todorova, T. I., da Silva Ferreira, M., Chen, J., Yu, Y., Mayer, J., Barreyro, L., et al. (2015) · Nature Medicine · doi:10.1038/nm.3936 · Cited by 127
Huang, C., Bredemeyer, A. L., Walker, L. M., Bassing, C. H., & Sleckman, B. P. (2008) · European Journal of Immunology · doi:10.1002/eji.200737972 · Cited by 125 · cited 2×
“SJL-PtprcaPepcb/BoyJ (Boy/J) mice, GFP-Myc mice (Huang et al., 2008), and Col1a1-TetO::rtTA-H2BGFP mice (Foudi et al.”
BackgroundOmacetaxine: a protein translation inhibitor for treatment of chronic myelogenous leukemia
Gandhi, V., Plunkett, W., & Cortes, J. E. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1283 · Cited by 118
Porse, B. T., Bryder, D., Theilgaard-Mönch, K., Hasemann, M. S., Anderson, K., Damgaard, I., Jacobsen, S. E. W., & Nerlov, C. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050067 · Cited by 117
Hosokawa, H., Ungerbäck, J., Wang, X., Matsumoto, M., Nakayama, K. I., Cohen, S. M., Tanaka, T., & Rothenberg, E. V. (2018) · Immunity · doi:10.1016/j.immuni.2018.04.024 · Cited by 116
The rate of protein synthesis in hematopoietic stem cells is limited partly by 4E-BPs
Signer, R. A. J., Qi, L., Zhao, Z., Thompson, D., Sigova, A. A., Fan, Z. P., DeMartino, G. N., Young, R. A., Sonenberg, N., & Morrison, S. J. (2016) · Genes & Development · doi:10.1101/gad.282756.116 · Cited by 115 · cited 2×
“The importance of eIFs in initiating HSC cell cycle activity has been illustrated by elegant work in which dual deletion of 4E-BP1/2, which negatively regulates translation by inhibiting eIF4E, leads to increased protein synthesis, aberrant cell cycle activity, and HSC expansion (Signer et al., 2016).”
BackgroundOikawa, T., Yamada, T., Kihara-Negishi, F., Yamamoto, H., Kondoh, N., Hitomi, Y., & Hashimoto, Y. (1999) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4400534 · Cited by 109 · cited 1×
“1 is commonly characterized as a lineage differentiation factor, its role as a regulator of cell proliferation has also been extensively studied (Delestré et al., 2017; Fukuchi et al., 2008; Oikawa et al., 1999; Solomon et al., 2017; Ziliotto et al., 2014).”
BackgroundZhang, B., Chu, S., Agarwal, P., Campbell, V. L., Hopcroft, L., Jørgensen, H. G., Lin, A., Gaal, K., Holyoake, T. L., & Bhatia, R. (2016) · Blood · doi:10.1182/blood-2015-11-679928 · Cited by 108
Ågerstam, H., Hansen, N., von Palffy, S., Sandén, C., Reckzeh, K., Karlsson, C., Lilljebjörn, H., Landberg, N., Askmyr, M., Högberg, C., et al. (2016) · Blood · doi:10.1182/blood-2015-11-679985 · Cited by 98 · cited 1×
“Aberrant signaling via IL-1 and the downstream IL-1 receptor associated kinase/TNF receptor associated factor pathway shared by IL-1R and TLRs has been implicated as a driver of survival and/or expansion of MDS and myeloid leukemia stem cells (Ågerstam et al., 2016; Askmyr et al., 2013; Barreyro et al., 2012; Carey et…”
BackgroundIL1RAP potentiates multiple oncogenic signaling pathways in AML
Mitchell, K., Barreyro, L., Todorova, T. I., Taylor, S. J., Antony-Debré, I., Narayanagari, S.-R., Carvajal, L. A., Leite, J., Piperdi, Z., Pendurti, G., et al. (2018) · Journal of Experimental Medicine · doi:10.1084/jem.20180147 · Cited by 97 · cited 1×
“Indeed, blockade of these pathways can limit and/or reverse disease progression (Carey et al., 2017; Mitchell et al., 2018; Rhyasen et al., 2013; Zhang et al., 2016); however, the mechanism(s) by which inflammatory signaling initiates expansion of oncogenically mutated HSCs remain obscure.”
BackgroundInflammation triggers emergency granulopoiesis through a density-dependent feedback mechanism
Cain, D. W., Snowden, P. B., Sempowski, G. D., & Kelsoe, G. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019957 · Cited by 95
Impact of constitutional TET2 haploinsufficiency on molecular and clinical phenotype in humans
Kaasinen, E., Kuismin, O., Rajamäki, K., Ristolainen, H., Aavikko, M., Kondelin, J., Saarinen, S., Berta, D. G., Katainen, R., Hirvonen, E. A. M., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09198-7 · Cited by 92
Translate to divide: сontrol of the cell cycle by protein synthesis
Department of Biochemistry and Biophysics, T. A. U., Polymenis, M., Aramayo, R., & Department of Biology, T. A. U. (2015) · Microbial Cell · doi:10.15698/mic2015.04.198 · Cited by 91 · cited 1×
“Hence, in eukaryotic cells, deletion and/or knockdown of key genes regulating protein synthesis, such as translation elongation initiation factors (eIFs), several of which are repressed by IL-1 in our dataset, results in delayed cell cycle entry (Polymenis and Aramayo, 2015).”
BackgroundInterconversion between Tumorigenic and Differentiated States in Acute Myeloid Leukemia
McKenzie, M. D., Ghisi, M., Oxley, E. P., Ngo, S., Cimmino, L., Esnault, C., Liu, R., Salmon, J. M., Bell, C. C., Ahmed, N., et al. (2019) · Cell Stem Cell · doi:10.1016/j.stem.2019.07.001 · Cited by 91 · cited 2×
“On the other hand, loss-of function mutations in PU.1 itself are rarely observed in hematological malignancy, though a wide array of myeloid leukemia-associated oncogenic lesions can interfere with PU.1 expression or function, including PML/RARA, AML1-ETO, NPM1c, and mitogenic kinase mutations in BCR/ABL and Flt3ITD (…”
BackgroundSelf-citationTo translate, or not to translate: viral and host mRNA regulation by interferon-stimulated genes
Li, M. M. H., MacDonald, M. R., & Rice, C. M. (2015) · Trends in Cell Biology · doi:10.1016/j.tcb.2015.02.001 · Cited by 90 · cited 1×
“, 2019), suggesting that other mechanism(s) may enforce HSC quiescence under chronic IFN stimulation, such as activation of p53 and/or themRNA translation-blocking activity of several IFN-stimulated genes (Li et al., 2015; Pietras et al., 2014).”
BackgroundIrgm1 protects hematopoietic stem cells by negative regulation of IFN signaling
King, K. Y., Baldridge, M. T., Weksberg, D. C., Chambers, S. M., Lukov, G. L., Wu, S., Boles, N. C., Jung, S. Y., Qin, J., Liu, D., et al. (2011) · Blood · doi:10.1182/blood-2011-01-328682 · Cited by 88 · cited 1×
“This is particularly true under inflammatory stress conditions, where increased proliferative activity can lead to functional attrition and/or aberrant expansion of the HSC compartment, including in the contexts of chronic infection and/or genetic mutation associated with BM failure and myeloid oncogenesis (Essers et…”
BackgroundC/EBPα deregulation as a paradigm for leukemogenesis
Pulikkan, J. A., Tenen, D. G., & Behre, G. (2017) · Leukemia · doi:10.1038/leu.2017.229 · Cited by 79
Stevens, B. M., Khan, N., D’Alessandro, A., Nemkov, T., Winters, A., Jones, C. L., Zhang, W., Pollyea, D. A., & Jordan, C. T. (2018) · Nature Communications · doi:10.1038/s41467-018-05984-x · Cited by 78 · cited 1×
“Food and Drug Administration–approved therapy for chronic myelogenous leukemia and can directly ablate MDS stem cells with aberrant levels of protein synthesis (Stevens et al., 2018).”
BackgroundSelf-citationWeisser, M., Demel, U. M., Stein, S., Chen-Wichmann, L., Touzot, F., Santilli, G., Sujer, S., Brendel, C., Siler, U., Cavazzana, M., et al. (2016) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2015.11.028 · Cited by 77
fastER: a user-friendly tool for ultrafast and robust cell segmentation in large-scale microscopy
Hilsenbeck, O., Schwarzfischer, M., Loeffler, D., Dimopoulos, S., Hastreiter, S., Marr, C., Theis, F. J., & Schroeder, T. (2017) · Bioinformatics · doi:10.1093/bioinformatics/btx107 · Cited by 74
Self-citationMYC Promotes Bone Marrow Stem Cell Dysfunction in Fanconi Anemia
Rodríguez, A., Zhang, K., Färkkilä, A., Filiatrault, J., Yang, C., Velázquez, M., Furutani, E., Goldman, D. C., Teresa, B. G., Garza-Mayén, G., et al. (2020) · Cell stem cell · doi:10.1016/j.stem.2020.09.004 · Cited by 72
Freire, P. R., & Conneely, O. M. (2018) · Blood · doi:10.1182/blood-2017-07-795757 · Cited by 70
Kihara-Negishi, F., Yamamoto, H., Suzuki, M., Yamada, T., Sakurai, T., Tamura, T., & Oikawa, T. (2001) · Oncogene · doi:10.1038/sj.onc.1204756 · Cited by 69
Inflammatory signals directly instruct PU.1 in HSCs via TNF
Etzrodt, M., Ahmed, N., Hoppe, P. S., Loeffler, D., Skylaki, S., Hilsenbeck, O., Kokkaliaris, K. D., Kaltenbach, H.-M., Stelling, J., Nerlov, C., et al. (2019) · Blood · doi:10.1182/blood-2018-02-832998 · Cited by 67
Self-citationMitotic History Reveals Distinct Stem Cell Populations and Their Contributions to Hematopoiesis
Säwén, P., Lang, S., Mandal, P., Rossi, D. J., Soneji, S., & Bryder, D. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.02.073 · Cited by 63 · cited 2×
“We induced H2B-GFP transgene for 2 wk with doxycycline chow (Säwén et al., 2016) followed by a 1-wk rest and subsequent chase period of 20 d with or without IL-1 injection.”
MethodHernandez, G., Mills, T. S., Rabe, J. L., Chavez, J. S., Kuldanek, S., Kirkpatrick, G., Noetzli, L., Jubair, W. K., Zanche, M., Myers, J. R., et al. (2020) · Haematologica · doi:10.3324/haematol.2018.197210 · Cited by 58
Self-citationMyelopoiesis, metabolism and therapy: a crucial crossroads in cancer progression
Sica, A., Guarneri, V., & Gennari, A. (2019) · Cell Stress · doi:10.15698/cst2019.09.197 · Cited by 58 · cited 1×
“We find these effects are coupled with excess myeloid lineage expansion reminiscent of early hematological malignancy (Sica et al., 2019).”
BackgroundERα promotes murine hematopoietic regeneration through the Ire1α-mediated unfolded protein response
Chapple, R. H., Hu, T., Tseng, Y.-J., Liu, L., Kitano, A., Luu, V., Hoegenauer, K. A., Iwawaki, T., Li, Q., & Nakada, D. (2018) · eLife · doi:10.7554/elife.31159 · Cited by 57
Higa, K. C., Goodspeed, A., Chavez, J. S., De Dominici, M., Danis, E., Zaberezhnyy, V., Rabe, J. L., Tenen, D. G., Pietras, E. M., & DeGregori, J. (2021) · Journal of Experimental Medicine · doi:10.1084/jem.20200560 · Cited by 57
Self-citationChronic Infection Depletes Hematopoietic Stem Cells through Stress-Induced Terminal Differentiation
Matatall, K. A., Jeong, M., Chen, F., Chen, S., Sun, D., Mo, Q., Kimmel, M., & King, K. Y. (2016) · Blood · doi:10.1182/blood.v128.22.732.732 · Cited by 52
Rabe, J. L., Hernandez, G., Chavez, J. S., Mills, T. S., Nerlov, C., & Pietras, E. M. (2020) · Experimental Hematology · doi:10.1016/j.exphem.2019.12.003 · Cited by 49 · cited 10×
“) in a 100 μl bolus once per day for either one or 20 days, as previously described (Pietras et al., 2016; Rabe et al., 2020).”
BackgroundMethodResultInfluentialSelf-citationDetecting Hematopoietic Stem Cell Proliferation Using BrdU Incorporation
Matatall, K. A., Kadmon, C. S., & King, K. Y. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-7371-2_7 · Cited by 40
PI3K alpha and delta promote hematopoietic stem cell activation
Hemmati, S., Sinclair, T., Tong, M., Bartholdy, B., Okabe, R. O., Ames, K., Ostrodka, L., Haque, T., Kaur, I., Mills, T. S., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.125832 · Cited by 40 · cited 2×
“, 2014), TNF (Yamashita and Passegue, 2019) and interleukin (IL)-1 (Hemmati et al., 2019; Weisser et al., 2016).”
BackgroundSelf-citationIdentification of immune-activated hematopoietic stem cells
Bujanover, N., Goldstein, O., Greenshpan, Y., Turgeman, H., Klainberger, A., Scharff, Y., & Gazit, R. (2018) · Leukemia · doi:10.1038/s41375-018-0220-z · Cited by 39 · cited 1×
“Highly enriched HSC fractions can maintain a quiescent phenotype and long-term engraftment capacity even under a variety of inflammatory stress conditions (Bujanover et al., 2018; Hernandez et al., 2020; Pietras et al., 2014; Pietras et al., 2016; Rabe et al., 2020; Wilson et al., 2008; Zhao et al., 2019), implying th…”
BackgroundEhninger, A., Boch, T., Uckelmann, H., Essers, M. A., Müdder, K., Sleckman, B. P., & Trumpp, A. (2014) · Blood · doi:10.1182/blood-2013-10-531038 · Cited by 36
Senescence is a Spi1-induced anti-proliferative mechanism in primary hematopoietic cells
Delestré, L., Cui, H., Esposito, M., Quiveron, C., Mylonas, E., Penard-Lacronique, V., Bischof, O., & Guillouf, C. (2017) · Haematologica · doi:10.3324/haematol.2016.157636 · Cited by 32 · cited 1×
“PU.1 has previously been characterized as a negative regulator of cell proliferation (Delestre et al., 2017; Fukuchi et al., 2008; Oikawa et al., 1999; Solomon et al., 2017; Ziliotto et al., 2014).”
BackgroundMouse and human HSPC immobilization in liquid culture by CD43- or CD44-antibody coating
Loeffler, D., Wang, W., Hopf, A., Hilsenbeck, O., Bourgine, P. E., Rudolf, F., Martin, I., & Schroeder, T. (2018) · Blood · doi:10.1182/blood-2017-07-794131 · Cited by 32 · cited 2×
“Single-cell tracking analysis Time-lapse experiments were conducted at 37°C, 5% O2, 5% CO2 on μ-slide VI0,4 channels slides (IBIDI) coated for 1 h at RTwith 5 or 10 μg/ml anti-CD43-biotin, as previously described (Loeffler et al., 2018).”
MethodSelf-citationYang, H., Liang, H., Yan, J.-S., Tao, R., Hao, S., & Ma, L. (2012) · International Journal of Hematology · doi:10.1007/s12185-012-1106-x · Cited by 27
Noguera, N. I., Piredda, M. L., Taulli, R., Catalano, G., Angelini, G., Gaur, G., Nervi, C., Voso, M. T., Lunardi, A., Pandolfi, P. P., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11964 · Cited by 27 · cited 3×
“On the other hand, loss-of function mutations in PU.1 itself are rarely observed in hematological malignancy, though a wide array of myeloid leukemia-associated oncogenic lesions can interfere with PU.1 expression or function, including PML/RARA, AML1-ETO, NPM1c, and mitogenic kinase mutations in BCR/ABL and Flt3ITD (…”
BackgroundPten Cell Autonomously Modulates the Hematopoietic Stem Cell Response to Inflammatory Cytokines
Porter, S. N., Cluster, A. S., Signer, R. A. J., Voigtmann, J., Monlish, D. A., Schuettpelz, L. G., & Magee, J. A. (2016) · Stem Cell Reports · doi:10.1016/j.stemcr.2016.04.008 · Cited by 22 · cited 1×
“Nature 510, 393-396. Rosenbauer, F., Wagner, K., Kutok, J.L., Iwasaki, H., Le Beau, M.M., Okuno, Y., Akashi, K., Fiering, S., and Tenen, D.G. (2004). Acute myeloid leukemia induced by graded reduction of a lineage-specific transcription factor, PU.”
Solomon, L. A., Podder, S., He, J., Jackson-Chornenki, N. L., Gibson, K., Ziliotto, R. G., Rhee, J., & DeKoter, R. P. (2017) · Molecular and Cellular Biology · doi:10.1128/mcb.00013-17 · Cited by 22 · cited 1×
“1 is commonly characterized as a lineage differentiation factor, its role as a regulator of cell proliferation has also been extensively studied (Delestré et al., 2017; Fukuchi et al., 2008; Oikawa et al., 1999; Solomon et al., 2017; Ziliotto et al., 2014).”
BackgroundFukuchi, Y., Ito, M., Shibata, F., Kitamura, T., & Nakajima, H. (2008) · Stem Cells · doi:10.1634/stemcells.2008-0320 · Cited by 20 · cited 2×
“1 accumulation during myeloid differentiation (Fukuchi et al., 2008; Kueh et al., 2013).”
BackgroundSelf-citationPU.1 promotes cell cycle exit in the murine myeloid lineage associated with downregulation of E2F1
Ziliotto, R. G., Gruca, M. R., Podder, S., Noel, G., Ogle, C. K., Hess, D. A., & DeKoter, R. P. (2013) · Experimental Hematology · doi:10.1016/j.exphem.2013.11.011 · Cited by 16
Hematopoietic stem cells, infection, and the niche
Prendergast, Á. M., & Essers, M. A. G. (2014) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12400 · Cited by 14 · cited 1×
“At least some portion of the HSC pool can be briefly forced out of quiescence to facilitate blood system regeneration by stressors such as infection (Prendergast and Essers, 2014), chronic stress (Heidt et al.”
BackgroundEzaki, K., Tsuzuki, M., Katsuta, I., Maruyama, F., Kojima, H., Okamoto, M., Nomura, T., Wakita, M., Miyazaki, H., Sobue, R., et al. (1995) · Leukemia Research · doi:10.1016/0145-2126(94)00064-h · Cited by 12 · cited 2×
“On the other hand, loss-of function mutations in PU.1 itself are rarely observed in hematological malignancy, though a wide array of myeloid leukemia-associated oncogenic lesions can interfere with PU.1 expression or function, including PML/RARA, AML1-ETO, NPM1c, and mitogenic kinase mutations in BCR/ABL and Flt3ITD (…”
BackgroundAnalysis of Murine Hematopoietic Stem Cell Proliferation During Inflammation
Jalbert, E., & Pietras, E. M. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-7371-2_14 · Cited by 12
Self-citation
Cited by
Caiado, F., Pietras, E. M., & Manz, M. G. (2021) · Journal of Experimental Medicine · doi:10.1084/jem.20201541 · Cited by 289
“1-deficient HSCs are largely insensitive to this effect of IL-1, fail to repress Myc, and instead continue to proliferate and expand in the BM (Chavez et al., 2021) during IL-1 exposure.”
BackgroundSelf-citationOu, X., Wang, H., Tie, H., Liao, J., Luo, Y., Huang, W., Yu, R., Song, L., & Zhu, J. (2023) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-01919-x · Cited by 229
Aging drives Tet2 +/− clonal hematopoiesis via IL-1 signaling
Caiado, F., Kovtonyuk, L. V., Gonullu, N. G., Fullin, J., Boettcher, S., & Manz, M. G. (2023) · Blood · doi:10.1182/blood.2022016835 · Cited by 161
Hematopoietic stem cells through the ages: A lifetime of adaptation to organismal demands
Kasbekar, M., Mitchell, C. A., Proven, M. A., & Passegué, E. (2023) · Cell Stem Cell · doi:10.1016/j.stem.2023.09.013 · Cited by 132
Made to order: emergency myelopoiesis and demand-adapted innate immune cell production
Swann, J. W., Olson, O. C., & Passegue, E. A. (2024) · Nature reviews. Immunology · doi:10.1038/s41577-024-00998-7 · Cited by 116
“In particular, IL-1 and IFNγ signalling drive clonal expansion of Tet2 -mutant and Dnmt3a -mutant HSCs, respectively, in murine models 179,181 .”
Influential
Metadata
- Authors
- Chavez, J. S., Rabe, J. L., Loeffler, D., Higa, K. C., Hernandez, G., Mills, T. S., Ahmed, N., Gessner, R. L., Ke, Z., Idler, B. M., Niño, K. E., Kim, H., Myers, J. R., Stevens, B. M., Davizon-Castillo, P., Jordan, C. T., Nakajima, H., Ashton, J., Welner, R. S., Schroeder, T., DeGregori, J., & Pietras, E. M.
- Affiliations
- University of Colorado Anschutz (US)
- ETH Zurich (CH)
- University of Rochester (US)
- Department of Pediatrics, University of Colorado Anschutz Medical Campus, Aurora, CO 9
- Yokohama City University (JP)
- University of Alabama at Birmingham (US)
- Corresponding author
- Pietras, Eric M.
- ORCID
- Chavez, James S.
- Rabe, Jennifer L.
- Loeffler, Dirk
- Higa, Kelly C.
- Hernandez, Giovanny
- Mills, Taylor S.
- Ahmed, Nouraiz
- Gessner, Rachel L.
- Ke, Zhonghe
- Idler, Beau M.
- Niño, Katia E.
- Kim, Hyunmin
- Myers, Jason R.
- Stevens, Brett M.
- Davizon-Castillo, Pavel
- Jordan, Craig T.
- Nakajima, Hideaki
- Ashton, John
- Welner, Robert S.
- Schroeder, Timm
- DeGregori, James
- Pietras, Eric M.
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2021-04-15
- Volume
- 218
- Issue
- 6
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- PMC
- PMC8056754
- OpenAlex
- W3156682036
- Semantic Scholar
- 0d4c6e501e7ab1ae5a80340cc5aac0dc7be1a2d9
- Cited by
- 91
- References
- 112
- Citations by year
- 2026: 16 · 2025: 12 · 2024: 16 · 2023: 20 · 2022: 16 · 2021: 10
- FWCI
- 10.37
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Journal of Experimental Medicine (publishedVersion, cc-by-nc-sa)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Repository for Publications and Research Data (ETH Zurich) (submittedVersion, cc-by-nc-nd)
- Repository for Publications and Research Data (ETH Zurich) (submittedVersion, cc-by-nc-sa)
- ETH Zürich Research Collection
- Funders
- National Institutes of Health (R01 DK119394, K01 DK098315, R01 AG067584, F31 HL138754, F30 CA210383, T32 AG000279)
- Boettcher Webb-Waring Early Career Investigator Award
- Cleo Meador and George Ryland Scott Endowed Chair in Hematology
- Swiss National Science Foundation (179490)
- National Science Foundation
- University of Colorado Cancer Center
- National Cancer Institute (P30 CA046934)
- Topics
- Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
- Health Sciences › Medicine › Hematology › Blood disorders and treatments
- Keywords
- PU.1, hematopoietic stem cells, HSC quiescence, HSC expansion, interleukin-1, inflammation, transcriptional repression, HSC homeostasis, innate immune signaling
- MeSH terms
- Proto-Oncogene Protein Spi-1, Animals, Cell Cycle, Cell Differentiation, Hematopoietic Stem Cells, Homeostasis, Immunity, Innate, Inflammation, Mice, Inbred C57BL, Proto-Oncogene Proteins, Stress, Physiological, Trans-Activators, Cell Proliferation, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.